Pub Date : 2024-01-01DOI: 10.31838/ijpr/2023.15.04.002
{"title":"An Updated Assessment Of Ritonavir: A Protease Inhibitor","authors":"","doi":"10.31838/ijpr/2023.15.04.002","DOIUrl":"https://doi.org/10.31838/ijpr/2023.15.04.002","url":null,"abstract":"","PeriodicalId":14220,"journal":{"name":"International Journal of Pharmaceutical Research","volume":"79 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139538542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.31838/ijpr/2023.15.03.011
{"title":"Efficacy of corticosteroid combined with hyalase compared to plain corticosteroid in intra-articular injections into the shoulder for adhesive capsulitis in Indian population","authors":"","doi":"10.31838/ijpr/2023.15.03.011","DOIUrl":"https://doi.org/10.31838/ijpr/2023.15.03.011","url":null,"abstract":"","PeriodicalId":14220,"journal":{"name":"International Journal of Pharmaceutical Research","volume":"120 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139638221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.31838/ijpr/2023.15.01.015
{"title":"Impact Of Predisposing Factors To Chemotherapy Induced Adverse Drug Reactions In Cancer Patients","authors":"","doi":"10.31838/ijpr/2023.15.01.015","DOIUrl":"https://doi.org/10.31838/ijpr/2023.15.01.015","url":null,"abstract":"","PeriodicalId":14220,"journal":{"name":"International Journal of Pharmaceutical Research","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74460986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.31838/ijpr/2021.14.01.002
{"title":"In Vivo Antidiarrheal Activity of Bile Content of Catla Catla.","authors":"","doi":"10.31838/ijpr/2021.14.01.002","DOIUrl":"https://doi.org/10.31838/ijpr/2021.14.01.002","url":null,"abstract":"","PeriodicalId":14220,"journal":{"name":"International Journal of Pharmaceutical Research","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88818757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.31838/ijpr/2022.14.01.012
{"title":"Case Study on Diabetic Ketoacidosiswith Type-1 Diabetes Mellitus in Adults","authors":"","doi":"10.31838/ijpr/2022.14.01.012","DOIUrl":"https://doi.org/10.31838/ijpr/2022.14.01.012","url":null,"abstract":"","PeriodicalId":14220,"journal":{"name":"International Journal of Pharmaceutical Research","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82017472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.31838/ijpr/2022.14.02.004
{"title":"Preparation and Evaluation of Fermented Ayurvedic Formulation forAnti-ulcerogenic activity","authors":"","doi":"10.31838/ijpr/2022.14.02.004","DOIUrl":"https://doi.org/10.31838/ijpr/2022.14.02.004","url":null,"abstract":"","PeriodicalId":14220,"journal":{"name":"International Journal of Pharmaceutical Research","volume":"119 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75801740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.31838/ijpr/2022.14.01.005
{"title":"Antidiabetic Activity Of Selenicereus Undatus (Haw). Fruit Extract Against Alloxan Induced Diabetic Mice","authors":"","doi":"10.31838/ijpr/2022.14.01.005","DOIUrl":"https://doi.org/10.31838/ijpr/2022.14.01.005","url":null,"abstract":"","PeriodicalId":14220,"journal":{"name":"International Journal of Pharmaceutical Research","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72933285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.31838/ijpr/2022.14.02.001
C. Suriyan, J. Martina, T. Sathishkumar, R. Ramesh, G. Prasannaraj
To evaluate the efficacy and safety of synthesized drug OUTBREAK, an Ayurvedic formulation for fever of viral origin in mild and moderate COVID19 positive patients. This is the prospective, randomized, multicentre, open label, parallel group interventional clinical endpoint study. Patients coming for the general outpatient department, were screened for viral fever by using the hematological, Biochemical and microbiological antibody assays. One Hundred patients who satisfied the selection criteria were enrolled in the study. Participants were randomized into 2 groups with 50 patients in each group. Patients were given standard treatment. In addition, Tab. OUTBREAK of Bageo Pharmaceuticals Pvt. Ltd., was administered to test groups. There is a highly significant improvement (P<0.001) in the subjects temperature, fever score, headache and SpO2 suggesting a good Analgesic and antipyretic activity of OUTBREAK. There is asignificant improvement in platelet count in the OUTBREAK treated group (P<0.01) when compared to the control group, proving its efficacy intreating thrombocytopenia. The improvement (P<0.01) in the random Sugar level in the OUTBREAK treated group depicts the anti-diabetic property of OUTBREAK.The improvement (P<0.01) in the WBC count in the OUTBREAK treated group depicts the antiviral property of OUTBREAK. The overall quality of life was better in OUTBREAK treated group compared to the control group. There were no serious adverse events reported. OUTBREAK is safe and efficacious in reversing thrombocytopenia and thus normalizing the platelet counts and relieving the clinical signs and symptoms (fever, headache and SpO2) of viral fever associated with thrombocytopenia and other cases of viral fever without thrombocytopenia. OUTBREAK is having good anti-viral, anti-pyretic and immuno-modulatory property.
{"title":"A randomized clinical study to evaluate the efficacy and safety of OUTBREAK in mild and moderate COVID19 positive patients","authors":"C. Suriyan, J. Martina, T. Sathishkumar, R. Ramesh, G. Prasannaraj","doi":"10.31838/ijpr/2022.14.02.001","DOIUrl":"https://doi.org/10.31838/ijpr/2022.14.02.001","url":null,"abstract":"To evaluate the efficacy and safety of synthesized drug OUTBREAK, an Ayurvedic formulation for fever of viral origin in mild and moderate COVID19 positive patients. This is the prospective, randomized, multicentre, open label, parallel group interventional clinical endpoint study. Patients coming for the general outpatient department, were screened for viral fever by using the hematological, Biochemical and microbiological antibody assays. One Hundred patients who satisfied the selection criteria were enrolled in the study. Participants were randomized into 2 groups with 50 patients in each group. Patients were given standard treatment. In addition, Tab. OUTBREAK of Bageo Pharmaceuticals Pvt. Ltd., was administered to test groups. There is a highly significant improvement (P<0.001) in the subjects temperature, fever score, headache and SpO2 suggesting a good Analgesic and antipyretic activity of OUTBREAK. There is asignificant improvement in platelet count in the OUTBREAK treated group (P<0.01) when compared to the control group, proving its efficacy intreating thrombocytopenia. The improvement (P<0.01) in the random Sugar level in the OUTBREAK treated group depicts the anti-diabetic property of OUTBREAK.The improvement (P<0.01) in the WBC count in the OUTBREAK treated group depicts the antiviral property of OUTBREAK. The overall quality of life was better in OUTBREAK treated group compared to the control group. There were no serious adverse events reported. OUTBREAK is safe and efficacious in reversing thrombocytopenia and thus normalizing the platelet counts and relieving the clinical signs and symptoms (fever, headache and SpO2) of viral fever associated with thrombocytopenia and other cases of viral fever without thrombocytopenia. OUTBREAK is having good anti-viral, anti-pyretic and immuno-modulatory property.","PeriodicalId":14220,"journal":{"name":"International Journal of Pharmaceutical Research","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76257715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.31838/ijpr/2022.14.04.010
{"title":"Current Status Of Gene Therapy For Cancer Treatment","authors":"","doi":"10.31838/ijpr/2022.14.04.010","DOIUrl":"https://doi.org/10.31838/ijpr/2022.14.04.010","url":null,"abstract":"","PeriodicalId":14220,"journal":{"name":"International Journal of Pharmaceutical Research","volume":"71 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78107410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：